Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820233 · ClinicalTrials.gov registry record
Studies of Neuregulin/ERBB Signaling in Human Heart
A clinical trial of Heart Failure and Heart Disease, sponsored by Douglas B. Sawyer.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT02820233: Recruiting study of Heart Failure and Heart Disease, sponsored by Douglas B. Sawyer.
NCT02820233 is a study of Heart Failure and Heart Disease that is actively recruiting participants, run by Douglas B. Sawyer. The registered enrollment target is 80 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02820233, a study of Heart Failure and Heart Disease, is actively recruiting participants, sponsored by Douglas B. Sawyer.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Conditions Studied
Study Locations (1)
Maine
- Maine Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-06 |
| Est. Completion | 2029-06 |
What NCT02820233 shows while recruiting
NCT02820233 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.
NCT02820233 reports a single indexed study location in Maine.
Frequently Asked Questions
What is clinical trial NCT02820233 about?
NCT02820233 is a clinical study titled "Studies of Neuregulin/ERBB Signaling in Human Heart". This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
What is the current status of trial NCT02820233?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2015-06. Estimated completion is 2029-06.
What conditions does trial NCT02820233 study?
This clinical trial studies the following conditions: Heart Failure, Heart Disease, Vascular Disease.
Who is sponsoring clinical trial NCT02820233?
This trial is sponsored by Douglas B. Sawyer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02820233 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02820233's enrollment target sits among peer trials
80 229th of 397 higher than 167 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia